Washington State legislation on biosimilars

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Washington State legislation on biosimilars

INICIO/Políticas y legislación | Posted 07/02/2014 0 Post your comment

Biologicals manufacturers represented by the Biotechnology Industry Association (BIO) and the Washington Biotechnology & Biomedical Association have welcomed proposed Washington State legislation that will support the substitution of interchangeable biological medicines.

Two bills (HB 2326 and SB 6091) from the Washington State House and Senate concern the prescription of biological products. They are the first legislative effort of their kind to be endorsed by a coalition of biologicals and biosimilars manufacturing companies.

The legislation includes transparent communication on all biological medicines dispensed in order to maintain a consistent and complete medical record. According to BIO, this will ensure transparency and communication between patients and their treatment teams, and is fully consistent with the BIO principles.

BIO’s principles include the safeguards that: the patient, or the patient’s authorized representative, should, at a minimum, be notified of the substitution of biological products; and that the pharmacist and the physician should keep records of the substitution. These two principles are particularly relevant to the treatment of chronic disease, where patients may have tried multiple regimens to find the safest, most effective therapy and where a disease evolves over time so accurate records must be kept.

In 2012, the US Food and Drug Administration (FDA) issued guidance on developing biosimilar products and is currently developing a pathway for the development and approval of safe and effective interchangeable biological products. It is vital that individual states, such as Washington, play a role in supporting transparent substitution practices and keeping physicians engaged in the process.

FDA defends the substitution of interchangeable biosimilars, with FDA Commissioner Margaret Hamburg saying in 2013 that attempts to undermine trust in biosimilars are ‘worrisome and represent a disservice to patients who could benefit from these lower-cost treatments [1].

Related articles

Pennsylvania moves closer to adopting biosimilars legislation

US FDA defends biosimilar substitution

Biotech firms try to limit biosimilar substitution in US

Reference

1. GaBI Online - Generics and Biosimilars Initiative. US state legislation on biosimilars substitution [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Feb 7]. Available from: www.gabionline.net/Policies-Legislation/US-state-legislation-on-biosimilars-substitution

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: BIO